Literature DB >> 18343994

Models for predicting BRCA1 and BRCA2 mutations in Han Chinese familial breast and/or ovarian cancer patients.

Nan-Yan Rao1, Zhen Hu, Wen-Feng Li, Juan Huang, Zhong-Liang Ma, Bin Zhang, Feng-Xi Su, Jie Zhou, Gen-Hong Di, Kun-Wei Shen, Jiong Wu, Jin-Song Lu, Jian-Min Luo, Wen-Tao Yuan, Zhen-Zhou Shen, Wei Huang, Zhi-Ming Shao.   

Abstract

PURPOSE: Our aim was to find an appropriate method to estimate the likelihood that a family history of cancer was a result of a mutation in the BRCA1 or BRCA2 genes. We also compared the performance of the established method with three different methods (Couch, Sh-E and BRCApro) to identify an alternative strategy for genetic council targeted to the specified population. PATIENTS AND METHODS: The family history as well as individual information of two hundred unrelated probands who had completed BRCA1 and BRCA2 mutation screening was analyzed to assess the likelihood of a pathogenic mutation. A model was developed by empirical method. The performance of this model was validated in a separate patient cohort compared with BRCApro.
RESULTS: Several factors were associated with mutations in univariate analysis and a logistic model was devised to estimate the probability for a proband of harboring a mutation in BRCA1 and/or BRCA2. Using a greater than 10% probability threshold, the highest accuracy was achieved by the established model when compared to other three models, presenting the highest sensitivity, PPV, NPV and area under ROC curve. The empirical model showed a better ROC curve compared to BRCApro in the verification cohort.
CONCLUSION: A probability model targeted to Han Chinese population should be a useful tool in the genetic counseling for the specified ethnic. Its ability to predict BRCA2 mutation carriers needs to be improved.

Entities:  

Mesh:

Year:  2008        PMID: 18343994     DOI: 10.1007/s10549-008-9965-9

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  6 in total

1.  Prediction of BRCA Mutations Using the BRCAPRO Model in Clinic-Based African American, Hispanic, and Other Minority Families in the United States.

Authors:  Dezheng Huo; Ruby T Senie; Mary Daly; Saundra S Buys; Shelly Cummings; Jacqueline Ogutha; Kisha Hope; Olufunmilayo I Olopade
Journal:  J Clin Oncol       Date:  2009-02-02       Impact factor: 44.544

2.  Breast cancer risk factors differ between Asian and white women with BRCA1/2 mutations.

Authors:  Monique A de Bruin; Ava Kwong; Benjamin A Goldstein; Jafi A Lipson; Debra M Ikeda; Lisa McPherson; Bhavna Sharma; Ani Kardashian; Elizabeth Schackmann; Kerry E Kingham; Meredith A Mills; Dee W West; James M Ford; Allison W Kurian
Journal:  Fam Cancer       Date:  2012-09       Impact factor: 2.375

3.  Performance of BRCA1/2 mutation prediction models in Asian Americans.

Authors:  Allison W Kurian; Gail D Gong; Nicolette M Chun; Meredith A Mills; Ashley D Staton; Kerry E Kingham; Beth B Crawford; Robin Lee; Salina Chan; Susan S Donlon; Yolanda Ridge; Karen Panabaker; Dee W West; Alice S Whittemore; James M Ford
Journal:  J Clin Oncol       Date:  2008-09-08       Impact factor: 44.544

4.  Performance of prediction models for BRCA mutation carriage in three racial/ethnic groups: findings from the Northern California Breast Cancer Family Registry.

Authors:  Allison W Kurian; Gail D Gong; Esther M John; Alexander Miron; Anna Felberg; Amanda I Phipps; Dee W West; Alice S Whittemore
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2009-03-31       Impact factor: 4.254

5.  Accuracy of BRCA1/2 mutation prediction models for different ethnicities and genders: experience in a southern Chinese cohort.

Authors:  Ava Kwong; Connie H N Wong; Dacita T K Suen; Michael Co; Allison W Kurian; Dee W West; James M Ford
Journal:  World J Surg       Date:  2012-04       Impact factor: 3.352

Review 6.  Hereditary breast cancer in the Han Chinese population.

Authors:  Wenming Cao; Xiaojia Wang; Ji-Cheng Li
Journal:  J Epidemiol       Date:  2013-01-12       Impact factor: 3.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.